Table 1.

Baseline demographic and clinical characteristics by New Approaches to Brain Tumor Therapy CNS Consortium (NABTT) trial.

	NABTT Trial
	9-AC	Suramin	Phenyl	Aprino	CPT-11	Procarb	Gliadel®	Gliasite	O6-BG	Onyx
Gender, % male	60	100	67	71	59	76	72	71	67	71
Race, % non-white	7	0	19	0	9	8	2	29	14	0
Age, median years	47	55	51	46	48	56	48	48	52	52
KPS, median	90	80	80	80	90	80	80	80	90	90
KPS, % 60-80	49	64	61	67	45	65	57	62	45	33
KPS, % 60-70	37	27	33	38	28	29	24	33	29	25
Initial histology, % GBM	56	73	58	67	72	56	70	71	81	73
On-study histology, % GBM	62	91	76	76	79	70	77	86	90	83
Time from initial dx, median months	12.8	10.7	10.2	9.4	11.0	11.5	9.1	9.5	10.3	13.6
Tumor outside frontal lobe, % yes	80	91	89	95	91	81	85	67	80	70
Corticosteroid use, % yes	60	82	84	75	70	58	81	86	71	61
Anticonvulsant use, % yes	69	91	84	81	72	86	12	67	88	68
Hemoglobin, median	14.0	13.8	12.7	12.9	13.2	14.2	14.1	*	13.8	14.5
Prior Chemotherapy, % >0	69	91	74	86	88	71	56	57	69	91
Prior Chemotherapy, % >1	10	36	37	38	7	4	17	14	21	32
Prior Surgery, % >1	71	64	47	52	47	51	30	29	38	9
Prior RT, % >1	19	27	21	5	3	0	0	14	0	5

Abbreviations: KPS, Karnofsky performance status; GBM, glioblastoma multiforme; dx, diagnosis; RT, radiation therapy

^*No hemoglobin data available for this study.